Clinical Trial Update: Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial of rociletinib in non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Rociletinib (CO-1686) (rociletinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN